AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02450903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750mg once daily
Study NCT00604539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (Condrosan)
Description: 800 mg (two capsules of 400 mg each) taken once a day for one year
Study NCT03187626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Study NCT00604539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
Study NCT00711711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
Study NCT00711711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: relaxation
Description: Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
Study NCT02279173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim subcutaneous weekly injection
Study NCT03187626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Study NCT00603993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
Study NCT05063669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Occupational Therapy
Description: In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
Study NCT02045368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-Methotrexate conjugate
Description: IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
Study NCT06747143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DN-114001
Description: Probiotic
Study NCT01941901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Intratumoral injection, once only treatment.
Study NCT01941901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Electrochemotherapy with bleomycin
Description: Intratumoral injection, once only treatment
Study NCT03903692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marine polysaccharide dressing
Description: The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
Study NCT03903692 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose dressing
Description: The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
Study NCT03339466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle therapy
Description: 6 weeks of inspiratory muscle therapy
Study NCT02473016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide Drug Delivery System (CDDS)
Description: Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
Study NCT00290355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 249553 vaccine
Description: Intramuscular injection, 13 doses
Study NCT00290355 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration, 13 doses
Study NCT03322592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid on-site evaluation (ROSE)
Description: On-site evaluation of the acquired samples will be performed by pathologist
Study NCT03322592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Histologic evaluation
Description: Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
Study NCT06761625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SanProbi® Barrier capsules
Description: The probiotic group received SanProbi® Barrier capsules
Study NCT06761625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group received capsules filled mainly with maize starch and maltodextrins.
Study NCT04070950 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Two self-questionnaires
Study NCT02655562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Study NCT02655562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Study NCT03427762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups.
Study NCT04535856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic mesenchymal stem cell
Description: Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)
Study NCT04535856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group (placebo)
Study NCT02124252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based testing with standard linkage to care
Description: Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
Study NCT02124252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based HPV testing with enhanced linkage to care
Description: Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
Study NCT00573105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ventral hernia repair by heavy weight mesh
Description: Laparoscopic Ventral hernia repair by heavy weight mesh
Study NCT00573105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ventral hernia repair by lighter weight mesh
Description: Laparoscopic Ventral hernia repair by lighter weight mesh
Study NCT01079806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
Study NCT01079806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
Study NCT01005615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-FES Upper Extremity Exercise
Description: While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
Study NCT01005615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RT300-SLSA, from Restorative Therapies, Inc.
Description: They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
Study NCT02509715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative nerve monitoring
Description: Intraoperative nerve monitoring during thyroid surgery
Study NCT02554006 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: good clinical practice
Description: education from physician regarding dual antiplatelet therapy as part of the routine discharge process
Study NCT03916198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
Study NCT03916198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
Study NCT02554006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bundle group
Description: visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
Study NCT02133144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overeating fat
Study NCT02133144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overeating carbohydrate
Study NCT03575780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 Ointment 1%
Description: The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
Study NCT03592134 — intervention group
Intervention type: OTHER
Intervention: esophageal pressure measurement
Description: Measurement of esophageal pressure to determine the optimal non invasive respiratory support
Study NCT02652572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Study NCT04205474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: graded bicycle test
Description: the subjects perform an exercise test on a reclining bicycle, and perform against increasing afterload
Study NCT00866606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benefix
Description: BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
Study NCT03032523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of care glucose test
Description: If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
Study NCT05093361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty for the treatment of hip arthritis.
Study NCT05093361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Self-driven training according to the training plan instructed by physical therapist.
Study NCT03769961 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No interventions - Observational study
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 5 mg, Single dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 20 mg, Single dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 60 mg, Single dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 150 mg, Single dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 300 mg, Single dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 600 mg, Single Dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [14C] BMS-813160
Description: Oral Solution, Oral, 150 mg, Single Dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 1200 mg, Single dose, 1 day
Study NCT01049165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-813160
Description: Oral Solution, Oral, 2000 mg, Single Dose, 1 day
Study NCT04285866 — intervention group
Intervention type: DRUG
Intervention: Durvalumab
Description: Durvalumab after chemoradiotherapy
Study NCT05333172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task exercises
Description: Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
Study NCT05333172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual task exercises
Description: Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
Study NCT00091130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HspE7
Description: Given SC
Study NCT00091130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given SC
Study NCT00091130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00091130 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00068250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2, intravenously three days prior to the first cycle of methotrexate
Study NCT00068250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
Study NCT00068250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 100 mg/m^2
Description: Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
Study NCT00068250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 150 mg/m^2
Description: Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
Study NCT00068250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide 200 mg/m^2
Description: Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
Study NCT00068250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
Study NCT00068250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-radiation therapy temozolomide
Description: Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
Study NCT02190357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
Study NCT04225936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986263
Description: Single Dose
Study NCT04620382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Midodrine 5-10 mg, single oral dose
Study NCT04620382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: single oral dose
Study NCT04620382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal compression
Description: abdominal compression up to 40 mmHg during head-up tilt
Study NCT04620382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham compression
Description: Sham abdominal compression during head-up tilt
Study NCT01044212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docusate
Description: Docusate 100mg BID
Study NCT01044212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowel medications
Description: Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
Study NCT03263923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention and journaling
Description: Cognitive behavioral skills training and 4 weeks of online journaling
Study NCT03263923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflective journaling
Description: Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling
Study NCT02567682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
Study NCT01245881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-ablative fractional photothermolysis laser
Description: * Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8.
Study NCT01245881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: broad-spectrum sunblock (SPF 50+)
Study NCT01057225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV
Study NCT01057225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study NCT01057225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally
Study NCT01057225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally